Cytokinetics, Incorporated
CYTK
$64.66
$1.151.81%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2,609.26% | 2,635.74% | 412.21% | 145.34% | -58.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,609.26% | 2,635.74% | 412.21% | 145.34% | -58.81% |
| Cost of Revenue | 22.52% | 18.85% | 7.65% | 2.81% | 3.31% |
| Gross Profit | 2.90% | 6.34% | -3.03% | 0.51% | -4.86% |
| SG&A Expenses | 29.32% | 34.08% | 34.07% | 24.02% | 7.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.06% | 24.25% | 16.57% | 10.12% | 4.81% |
| Operating Income | -9.21% | -8.08% | -13.59% | -8.07% | -5.81% |
| Income Before Tax | -30.45% | -11.19% | -15.96% | -12.03% | -9.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.45% | -11.19% | -15.96% | -12.03% | -9.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.45% | -11.19% | -15.96% | -12.03% | -9.43% |
| EBIT | -9.21% | -8.08% | -13.59% | -8.07% | -5.81% |
| EBITDA | -10.20% | -9.01% | -14.53% | -8.76% | -4.61% |
| EPS Basic | -17.08% | 4.66% | 1.75% | 3.20% | 2.39% |
| Normalized Basic EPS | -17.07% | 4.66% | 1.75% | 3.20% | 2.40% |
| EPS Diluted | -17.08% | 4.66% | 1.75% | 3.20% | 2.39% |
| Normalized Diluted EPS | -17.07% | 4.66% | 1.75% | 3.20% | 2.40% |
| Average Basic Shares Outstanding | 11.24% | 16.59% | 17.99% | 15.77% | 12.12% |
| Average Diluted Shares Outstanding | 11.24% | 16.59% | 17.99% | 15.77% | 12.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |